Supplementary Material


Supplementary File 1. Boolean operator for literature searching

Database	Keyword combination	Hits
PubMed	((((("Cervi* cancer"[Title/Abstract]) OR ("Cervi* neoplasm*"[Title/Abstract]))))) AND ((("Programmed Cell Death 1 Receptor"[Title/Abstract]) OR ("Programmed-death 1"[Title/Abstract])) OR (PD-1[Title/Abstract])) OR ("PD 1"[Title/Abstract])) OR ("Programmed Death-Ligand 1"[Title/Abstract])) OR ("Programmed Death Ligand 1"[Title/Abstract])) OR (PD-L1[Title/Abstract])) OR ("PD L1"[Title/Abstract])) OR (CD274[Title/Abstract])) OR ("Immune checkpoint inhibitor*"[Title/Abstract])) OR (Pembrolizumab[Title/Abstract])) OR (Keytruda[Title/Abstract])) OR (Nivolumab[Title/Abstract])) OR (Opdivo[Title/Abstract])) OR (Cemiplimab[Title/Abstract])) OR (Libtayo[Title/Abstract])) OR (Dostarlimab[Title/Abstract])) OR (Jemperli[Title/Abstract])) OR (Atezolizumab[Title/Abstract])) OR (Tecentriq[Title/Abstract])) OR (Durvalumab[Title/Abstract])) OR (Imfinzi[Title/Abstract])) OR (Avelumab[Title/Abstract])) OR (Bavencio[Title/Abstract])) OR (Ipilimumab[Title/Abstract])) OR (Yervoy[Title/Abstract])) OR (Camrelizumab[Title/Abstract])) OR (AiRuiKa[Title/Abstract])) OR (Sintilimab[Title/Abstract])) OR (Tyvyt[Title/Abstract])) OR (Tislelizumab[Title/Abstract])) OR (Tevimbra[Title/Abstract])) OR (Toripalimab[Title/Abstract])) OR (Loqtorzi[Title/Abstract])) OR (Retifanlimab[Title/Abstract])) OR (Zynyz[Title/Abstract])) OR (Penpulimab[Title/Abstract])) OR (Serplulimab[Title/Abstract])) OR (Zimberelimab[Title/Abstract])) OR (Quming[Title/Abstract])) OR (Gofansonlimab[Title/Abstract])) OR (GenSTile[Title/Abstract])) OR (Pucotenlimab[Title/Abstract])) OR (Prolgolimab[Title/Abstract])) OR (Cosibelimab[Title/Abstract])) OR (Envafolimab[Title/Abstract])) OR (Sugemalimab[Title/Abstract])) OR (Cejemly[Title/Abstract])) OR (Adebrelimab[Title/Abstract])) OR (Arelib[Title/Abstract]))))) AND ((((Chemoradiotherapy*[Title/Abstract])) OR ("Concurrent Chemoradiotherapy*"[Title/Abstract])) OR (Radiochemotherapy*[Title/Abstract]))	94
Scopus	(TITLE-ABS-KEY ("Cervi* cancer" OR "Cervi* neoplasm*")) AND (TITLE-ABS-KEY ("Programmed Cell Death 1 Receptor" OR "Programmed death 1" OR PD-1 OR "PD 1" OR "Programmed Death-Ligand 1" OR "Programmed Death Ligand 1" OR PD-L1 OR "PD L1" OR CD274 OR "Immune checkpoint inhibitor*" OR Pembrolizumab OR Keytruda OR Nivolumab OR Opdivo OR Cemiplimab OR Libtayo OR Dostarlimab OR Jemperli OR Atezolizumab OR Tecentriq OR Durvalumab OR Imfinzi OR Avelumab OR Bavencio OR Dostarlimab OR Jemperli OR Camrelizumab OR AiRuiKa OR Sintilimab OR Tyvyt OR Tislelizumab OR Tevimbra OR Toripalimab OR Loqtorzi OR Retifanlimab OR Zynyz OR Penpulimab OR Anruike OR Serplulimab OR Hansizhuang OR Zimberelimab OR Quming OR Geptanolimab OR GES OR Pucotenlimab OR Felie OR Prolgolimab OR Fortecs OR Cosibelimab OR Envafolimab OR Enwenda OR Sugemalimab OR Cejemly OR Adebrelimab OR Arelib)) AND (TITLE-ABS-KEY (Chemoradiotherap* OR "Concurrent Chemoradiotherap*" OR Radiochemotherap*))	374
Cochrane Library	("Cervical cancer" OR "Cervical neoplasm"):ti,ab,kw AND ("Programmed Cell Death 1 Receptor" OR "Programmed death 1" OR PD-1 OR "PD 1" OR "Programmed Death-Ligand 1" OR PD-L1 OR "PD L1" OR CD274 OR "Immune checkpoint inhibitor" OR Pembrolizumab OR Keytruda OR Nivolumab OR Opdivo OR Cemiplimab OR Libtayo OR Dostarlimab OR Jemperli OR Atezolizumab OR Tecentriq OR Durvalumab OR Imfinzi OR Avelumab OR Bavencio OR Dostarlimab OR Jemperli OR Camrelizumab OR AiRuiKa OR Sintilimab OR Tyvyt OR Tislelizumab OR Tevimbra OR Toripalimab OR Loqtorzi OR Retifanlimab OR Zynyz OR Penpulimab OR Anruike OR Serplulimab OR Hansizhuang OR Zimberelimab OR Quming OR Geptanolimab OR GES OR Pucotenlimab OR Felie OR Prolgolimab OR Fortecs OR Cosibelimab OR Envafolimab OR Enwenda OR Sugemalimab OR Cejemly OR Adebrelimab OR Arelib):ti,ab,kw AND (Chemoradiotherapy* OR "Concurrent Chemoradiotherapy*" OR Radiochemotherapy*):ti,ab,kw	96
ProQuest	title("Cervi* cancer" OR "Cervi* neoplasm*") AND title("Programmed Cell Death 1 Receptor" OR "Programmed death 1" OR PD-1 OR "PD 1" OR "Programmed Death-Ligand 1" OR "Programmed Death Ligand 1" OR PD-L1 OR "PD L1" OR CD274 OR "Immune checkpoint inhibitor*" OR Pembrolizumab OR Keytruda OR Nivolumab OR Opdivo OR Cemiplimab OR Libtayo OR Dostarlimab OR Jemperli OR Atezolizumab OR Tecentriq OR Durvalumab OR Imfinzi OR Avelumab OR Bavencio) AND title("Chemoradiotherap*" OR "Concurrent Chemoradiotherap*" OR Radiochemotherap*)	28
Google Scholar	all-field: ("Cervi* cancer" OR "Cervi* neoplasm*") AND ("Programmed Cell Death 1 Receptor" OR "Programmed death 1" OR PD-1 OR "PD 1" OR "Programmed Death-Ligand 1" OR "Programmed Death Ligand 1" OR PD-L1 OR "PD L1" OR CD274 OR "Immune checkpoint inhibitor*" OR Pembrolizumab OR Keytruda OR Nivolumab OR Opdivo OR Cemiplimab OR Libtayo OR Dostarlimab OR Jemperli OR Atezolizumab OR Tecentriq OR Durvalumab OR Imfinzi OR Avelumab OR Bavencio) AND (Chemoradiotherap* OR "Concurrent Chemoradiotherap*" OR Radiochemotherap*)	407


Supplementary File 2. Clinical characteristic of 5 included studies

Study	Intervention	Type of cancer	Disease status at trial entry	Disease stage at initial diagnosis	Histology	Lymph node involvement	Previous therapy	Dose administration	Chemotherapy drug
Colombo et al.[101], 2021	Pembrolizumab + chemotherapy	PRMC	Metastatic: 58 Persistent or recurrent with distant metastases: 199 Persistent or recurrent without distant metastases: 51	I: 67 II: 85 III: 5 IIIA: 4 IIIB: 46 IVA: 5 IVB: 94	Adenocarcinoma: 56 Squamous-cell carcinoma: 15 Squamous-cell carcinoma: 233	NR	Chemoradiotherapy and surgery: 49 Radiotherapy and surgery: 22 Chemoradiotherapy only: 125 Radiotherapy only: 31 Surgery only: 23 None: 58	Concurrent: Pembrolizumab 200 mg IV q3w × up to 35 cycles Maintenance: Pembrolizumab 200 mg IV q3w × up to 35 cycles	Paclitaxel/ cisplatin/ carboplatin
	Placebo + chemotherapy		Metastatic: 64 Persistent or recurrent with distant metastases: 179 Persistent or recurrent without distant metastases:66	I: 58 II: 93 III: 8 IIIA: 8 IIIB: 42 IVA: 4 IVB: 96	Adenocarcinoma: 84 Adenosquamous carcinoma: 14 Squamous-cell carcinoma: 211	NR	Chemoradiotherapy and surgery: 56 Radiotherapy and surgery: 23 Chemoradiotherapy only: 118 Radiotherapy only: 24 Surgery only: 24 None: 64	Concurrent: Placebo IV q3w × up to 35 cycles Maintenance: Placebo IV q3w × up to 35 cycles	
Lorusso et al.[110], 2024	Pembrolizumab + chemotherapy	LAAC	NR	IB2 to IIB: 233 III to IVA: 296	Non-squamous: 95 Squamous: 434	Positive pelvic only: 327 Positive para-aortic only: 14 Positive pelvic and para- aortic: 104 No positive pelvic or para-aortic: 84	IMRT or VMAT: 469 Non-IMRT and non-VMAT: 60	Concurrent: Pembrolizumab 200 mg IV q3w × 5 cycles Maintenance: Pembrolizumab 400 mg IV q6w × 15 cycles	Paclitaxel + cisplatin/ carboplatin ± bevacizumab
	Placebo + chemotherapy		NR	IB2 to IIB: 226 III to IVA: 305	Non-squamous: 80 Squamous: 451	Positive pelvic only: 324 Positive para-aortic only: 10 Positive pelvic and para- aortic: 104 No positive pelvic or para-aortic: 93	IMRT or VMAT: 470 Non-IMRT and non-VMAT: 61	Concurrent: Placebo IV q3w × 5 cycles Maintenance: Placebo IV q6w × 15 cycles	
Monk et al.[106], 2023	Durvalumab + chemotherapy	LAAC	NR	IB2: 19 IIA: 21 IIB: 95 IIIA: 54 IIIB: 171 IVA: 25	Squamous carcinoma: 322 Adenocarcinoma: 55 Adenosquamous carcinoma: 8	Para-aortic lymph node: 15 No para-aortic lymph node: 97 Pelvic lymph node: 75 No pelvic lymph node: 37	NR	Concurrent: Durvalumab 1500 mg IV q4w × 5 cycles Maintenance: Durvalumab 1500 mg IV q4w × up to 24 cycles	Cisplatin/ carboplatin
	Placebo + chemotherapy		NR	IB2: 20 IIA: 13 IIB: 97 IIIA: 64 IIIB: 172 IVA: 19	Squamous carcinoma: 320 Adenocarcinoma: 58 Adenosquamous carcinoma: 7	Para-aortic lymph node: 20 No para-aortic lymph node: 108 Pelvic lymph node: 97 No pelvic lymph node: 31	NR	Concurrent: Placebo IV q4w × 5 cycles Maintenance: Placebo IV q4w × up to 24 cycles	
Oaknin et al.[105], 2024	Atezolizumab + chemotherapy	PRMC	Newly diagnosed metastatic disease (stage IVB): 43 Recurrent (includes patients with distant disease): 150 Persistent: 13	I: 31 II: 61 III not otherwise specified: 14 IIIA: 2 IIIB: 34 IV not otherwise specified: 5 IVA: 11 IVB: 63 Not assessed or pre-invasive: 4 Missing: 1	NR	Pelvic and distant: 102 Distant only: 71 Pelvic only: 33	Concurrent chemoradiotherapy: 70 Surgery: 9 Surgery followed by chemoradiotherapy: 64 Surgery followed by radiotherapy: 5 Primary radiotherapy: 2 None: 56	Concurrent: Atezolizumab 1200 mg IV q3w Maintenance: Atezolizumab 1200 mg IV q3w + bevacizumab 15 mg/kg IV q3w until 24 months	Cisplatin/ carboplatin
	Placebo + chemotherapy		Newly diagnosed metastatic disease (stage IVB): 47 Recurrent (includes patients with distant disease): 151 Persistent: 6	I: 42 II: 53 III not otherwise specified: 12 IIIA: 4 IIIB: 22 IV not otherwise specified: 8 IVA: 6 IVB: 50 Not assessed or pre-invasive: 5 Missing: 2	NR	Pelvic and distant: 90 Distant only: 74 Pelvic only: 40	Concurrent chemoradiotherapy: 85 Surgery: 14 Surgery followed by chemoradiotherapy: 44 Surgery followed by radiotherapy: 11 Primary radiotherapy: 3 None: 47	Concurrent: Paclitaxel 175 mg/m² IV q3w × 6 cycles Maintenance: Bevacizumab 15 mg/kg IV q3w until 24 months	
Wu et al.[206], 2024	Cadonilimab + chemotherapy	PRMC	NR	I: 47 II: 43 IIIA: 3 IIIB: 17 IIIC: 60 IVA: 2 IVB: 50 Unknown: 0	Squamous cell carcinoma: 182 Adenocarcinoma: 34 Adenosquamous carcinoma: 6	NR	(Chemo)radiotherapy and surgery: 73 (Chemo)radiotherapy only: 71 Neoadjuvant or adjuvant chemotherapy: 94 Surgery only: 31 None: 47	Concurrent: Cadonilimab 10 mg/kg IV q3w × 6 cycles Maintenance: Cadonilimab 10 mg/kg IV q3w (± bevacizumab) until 2 years	Paclitaxel + cisplatin/ carboplatin ± bevacizumab
	Placebo + chemotherapy		NR	I: 40 II: 54 IIIA: 3 IIIB: 17 IIIC: 62 IVA: 3 IVB: 42 Unknown: 2	Squamous cell carcinoma: 188 Adenocarcinoma: 29 Adenosquamous carcinoma: 6	NR	(Chemo)radiotherapy and surgery: 82 (Chemo)radiotherapy only: 72 Neoadjuvant or adjuvant chemotherapy: 96 Surgery only: 28 None: 41	Concurrent: Placebo IV q3w × 6 cycles Maintenance: Placebo IV q3w (± bevacizumab) until 2 years	

IMRT: Intensity-modulated radiation therapy, VMAT: Volumetric modulated arc therapy, PRMC: Persistent,recurrent, or metastatic cervical, LAAC: Locally advanced cervical cancer




(a)



(b)

Supplementary File 3. Pooled analysis of overall survival (**a**) and progression-free survival (PFS) among patients with a PD-L1 positive

PD-L1: Programmed death-ligand 1, HR: Hazard ratio, CI: Confidence interval




Intervention	Estimate	95%CI	p-value
Difference	1.20 m	-0.85 m to 3.24 m	0.251
Ratio	1.06	0.96 to 1.18	0.251

Intervention	Estimate	95%CI	p-value
Difference	1.77 m	-0.28 m to 3.81 m	0.09
Ratio	1.13	0.98 to 1.30	0.091

Supplementary File 4. Comparative analysis of OSR and PFSR at 6-24 months in PD-1 group. Time-point meta-proportion estimates are presented for OSR (**a**) and PFSR (**b**), while RMST plots are shown for OSR (**c**) and PFSR (**d**)

PD-1: Programmed death-1, CI: Confidence interval, RMST: Restricted mean survival time



Intervention	Estimate	95%CI	p-value
Difference	0.82 m	-1.91 m to 3.56 m	0.555
Ratio	1.04	0.91 to 1.19	0.555

Intervention	Estimate	95%CI	p-value
Difference	1.38 m	-1.36 m to 4.12 m	0.324
Ratio	1.09	0.92 to 1.28	0.325

Supplementary File 5. Comparative analysis of OSR and PFSR at 6-24 months in PD-L1 group. Time-point meta-proportion estimates are presented for OSR (**a**) and PFSR (**b**), while RMST plots are shown for OSR (**c**) and PFSR (**d**)

RMST: Restricted mean survival time, CI: Confidence interval


Supplementary File 6. Safety for any grade

Adverse event	Number of studies	OR (95% CI)	p-value
Abdominal pain	4	0.93 (0.74; 1.17)	0.53
Alanine aminotransferase increased	5	1.22 (0.92; 1.62)	0.16
Anemia	5	1.06 (0.91; 1.23)	0.45
Arthralgia	5	1.13 (0.81; 1.56)	0.48
Aspartate aminotransferase increased	4	1.51 (1.18; 1.92)	0.0009*
Asthenia	5	1.21 (0.89; 1.65)	0.22
Back pain	4	0.81 (0.70; 1.18)	0.47
Blood creatinine increased	4	1.03 (0.78; 1.35)	0.86
Constipation	5	1.09 (0.93; 1.29)	0.29
COVID-19	4	1.13 (0.78; 1.64)	0.50
Decreased appetite	5	1.28 (1.00; 1.65)	0.05*
Diarrhea	5	1.16 (0.89; 1.50)	0.27
Dysuria	4	1.04 (0.77; 1.40)	0.79
Headache	4	1.00 (0.78; 1.28)	0.99
Hypertension	2	0.89 (0.62; 1.26)	0.50
Hyperthyroidism	4	3.75 (2.57; 5.48)	<0.00001*
Hypokalaemia	4	1.21 (0.97; 1.51)	0.09
Hypomagnesaemia	4	1.12 (0.89; 1.41)	0.33
Hyponatraemia	4	1.13 (0.83; 1.53)	0.45
Hypothyroidism	5	3.29 (2.63; 4.12)	<0.00001*
Leukopenia	5	1.26 (1.01; 1.56)	0.04*
Lymphocyte count decreased	4	0.74 (0.56; 0.97)	0.03*
Lymphopenia	4	0.97 (0.75; 1.26)	0.84
Myalgia	2	1.34 (0.69; 2.57)	0.39
Nausea	5	0.97 (0.84; 1.11)	0.66
Neutropenia	5	1.25 (1.03; 1.53)	0.03*
Neutrophil count decreased	5	1.03 (0.85; 1.25)	0.76
Pelvic pain	4	0.96 (0.68; 1.35)	0.80
Platelet count decreased	5	0.98 (0.80; 1.20)	0.82
Pyrexia	4	1.56 (1.03; 2.34)	0.03*
Thrombocytopenia	5	1.10 (0.92; 1.31)	0.30
Urinary tract infection	4	0.98 (0.82; 1.17)	0.85
Vomiting	5	1.05 (0.85; 1.28)	0.66
Weight decreased	4	1.22 (0.86; 1.72)	0.26
White blood cell counts decreased	5	0.91 (0.69; 1.21)	0.53


Supplementary File 7. Safety for grade >3

Adverse event	Number of studies	OR (95% CI)	p-value
Abdominal pain	4	0.96 (0.46; 2.02)	0.92
Alanine aminotransferase increased	5	1.47 (0.78; 2.78)	0.24
Anemia	5	1.11 (0.79; 1.57)	0.55
Arthralgia	5	1.05 (0.26; 4.19)	0.95
Aspartate aminotransferase increased	4	1.86 (0.53; 6.48)	0.33
Asthenia	5	1.38 (0.49; 3.86)	0.55
Back pain	4	0.49 (0.12; 2.02)	0.33
Blood creatinine increased	4	0.64 (0.16; 2.53)	0.53
Constipation	5	0.97 (0.27; 3.50)	0.97
COVID-19	4	0.56 (0.05; 6.38)	0.64
Decreased appetite	5	3.16 (1.19; 8.39)	0.02*
Diarrhea	5	1.24 (0.77; 1.98)	0.38
Dysuria	4	1.41 (0.22; 8.95)	0.72
Headache	4	0.55 (0.11; 2.66)	0.46
Hypertension	2	0.93 (0.54; 1.61)	0.79
Hyperthyroidism	4	4.17 (0.78; 24.85)	0.12
Hypokalaemia	4	1.32 (0.86; 2.02)	0.20
Hypomagnesaemia	4	1.18 (0.61; 2.27)	0.62
Hyponatraemia	4	0.89 (0.39; 2.01)	0.78
Hypothyroidism	5	4.26 (0.90; 20.10)	0.77
Leukopenia	5	1.21 (0.90; 1.62)	0.21
Lymphocyte count decreased	4	0.79 (0.52; 1.19)	0.26
Lymphopenia	4	1.20 (0.87; 1.64)	0.26
Myalgia	2	0.67 (0.11; 4.03)	0.66
Nausea	5	1.00 (0.56; 1.79)	1.00
Neutropenia	5	1.26 (0.96; 1.66)	0.10
Neutrophil count decreased	5	0.94 (0.70; 1.28)	0.70
Pelvic pain	4	0.96 (0.38; 2.42)	0.92
Platelet count decreased	5	1.25 (0.90; 1.73)	0.19
Pyrexia	4	1.54 (0.56; 4.20)	0.40
Thrombocytopenia	5	1.32 (0.95; 1.82)	0.10
Urinary tract infection	4	1.11 (0.75; 1.64)	0.60
Vomiting	5	0.84 (0.44; 1.62)	0.60
Weight decreased	4	2.20 (0.89; 5.48)	0.09
White blood cell counts decreased	5	0.87 (0.64; 1.17)	0.35


CI: Confidence interval, OR: Odds ratio




(a)




(b)




(c)



(d)



(e)



(f)

Supplementary File 8. Forest plot of objective response rate (**a**), disease control rate (**b**), complete response (**c**), partial response (**d**), stable disease (**e**), and progressive disease (**f**)

CI: Confidence interval, RR: Risk ratio, PD-1: Programmed death-1, PD-L1: PD-ligand 1

Supplementary File 9. GRADE certainty of evidence for response rate outcomes

Outcome	Population	No of participants (k)	Relative effects RR (95% CI)	Certainty	What happens
ORR	Pooled	3,300 (5)	1.14 (1.02 to 1.26)	⨁⨁◯◯ Low	Immunochemotherapy slightly increases objective response rate compared with chemotherapy alone.
	PD-1	2,120 (3)	1.17 (0.98 to 1.40)	⨁⨁⨁◯ Moderate	PD-1-based regimens may improve response rates, although the effect is not statistically significant.
	PD-L1	1,180 (2)	1.09 (0.48 to 2.43)	⨁◯◯◯ Very low	The effect of PD-L1 inhibitors on tumor response is very uncertain due to heterogeneity and imprecision.
DCR	Pooled	3,302 (5)	1.09 (0.97 to 1.23)	⨁⨁◯◯ Low	Combination therapy may produce little or no difference in disease control rate.
	PD-1	2,122 (3)	1.10 (0.80 to 1.51)	⨁◯◯◯ Very low	Evidence is very uncertain regarding PD-1 effects on disease control.
	PD-L1	1,180 (2)	1.09 (0.48 to 2.43)	⨁◯◯◯ Very low	Evidence for PD-L1 inhibitors on disease control is highly uncertain.
CR	Pooled	3,285 (5)	1.3 (1.0 to 1.7)	⨁◯◯◯ Very low	Combination therapy may increase complete response, but certainty is very low.
	PD-1	2,105 (3)	1.36 (0.78 to 2.37)	⨁◯◯◯ Very low	The effect of PD-1 inhibitors on complete response remains uncertain.
	PD-L1	1,180 (2)	1.26 (0.11 to 14.41)	⨁◯◯◯ Very low	Evidence is extremely uncertain due to very wide confidence intervals.
PR	Pooled	3,285 (5)	1.02 (0.91 to 1.14)	⨁⨁⨁◯ Moderate	Combination therapy likely results in little or no difference in partial response.
	PD-1	2,105 (3)	1.04 (0.75 to 1.44)	⨁⨁◯◯ Low	PD-1 inhibitors may have no clear effect on partial response.
	PD-L1	1,180 (2)	1.00 (0.87 to 1.15)	⨁⨁◯◯ Low	PD-L1 inhibitors probably do not change partial response rates.
SD	Pooled	3,285 (5)	0.68 (0.45 to 1.03)	⨁⨁⨁◯ Moderate	Immunochemotherapy may reduce stable disease rates, but results remain uncertain.
	PD-1	2,105 (3)	0.62 (0.34 to 1.11)	⨁⨁⨁◯ Moderate	PD-1 inhibitors may reduce stable disease but evidence is not definitive.
	PD-L1	1,180 (2)	0.88 (0.01 to 108.86)	⨁◯◯◯ Very low	Evidence is extremely uncertain due to extreme heterogeneity and very wide CI.
PD	Pooled	3,285 (5)	0.39 (0.13 to 1.23)	⨁◯◯◯ Very low	Combination therapy may reduce progressive disease, but evidence is highly uncertain.
	PD-1	2,105 (3)	0.57 (0.25 to 1.31)	⨁⨁◯◯ Low	PD-1 inhibitors may reduce disease progression, but results are inconclusive.
	PD-L1	1,180 (2)	0.24 (0.00 to 502367.70)	⨁◯◯◯ Very low	Evidence is extremely uncertain due to extreme imprecision.

GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of the effect
GRADE: Grading of Recommendations, Assessment, Development and Evaluation, ORR: Objective response rate, DCR: Disease control rate, CR: Complete response, PR: Partial response, SD: Stable disease, PD: Progressive disease, RR: Risk ratio, CI: Confidence interval, PD-1: Programmed death-1, PD-L1: PD-ligand 1